Publications produced with ESRs contribution

1. Walter Melanie, Evert Homan, Tobias Koolmeister, Oliver Mortusewicz, Thomas Helleday and Patrick Herr.
   Development of Small Molecule NUDT22 Inhibitors for Uses in Cancer.
   Medical Science Forum, 2021, 3, 1. DOI: 10.3390/iecc2021-09197.
   Published abstract. Integrata is acknowledged on the published poster (supplementary information)
2. ElMokh O, Matsumoto S, Biniecka P, Bellotti A, Schaeuble K, Piacente F, Gallart-Ayala H, Ivanisevic J, Stamenkovic I, Nencioni A, Nahimana A, Duchosal MA.
   Gut microbiota severely hampers the efficacy of NAD-lowering therapy in leukemia.
   Cell Death Dis. 2022 Apr 8;13(4):320. DOI: 10.1038/s41419-022-04763-3.
3. Melanie Walter, & Patrick Herr.
   Re-Discovery of Pyrimidine Salvage as Target in Cancer Therapy.
   Cells, 2022, 11(4), 739. DOI: 10.3390/cells11040739.
4. Moustafa S. Ghanem, Irene Caffa, Alberto Del Rio, Jorge Franco, Marco Daniele Parenti, Fiammetta Monacelli, Michele Cea, Amr Khalifa, Aimable Nahimana, Michel A. Duchosal, Silvia Ravera, Nadia Bertola, Santina Bruzzone, Alessio Nencioni and Francesco Piacente.
   Identification of NAPRT Inhibitors with Anti-Cancer Properties by In Silico Drug Discovery.
   Pharmaceuticals, 2022, 15(7), 848. DOI: 10.3390/ph15070848.
5. Melanie Walter, Florian Mayr, Bishoy Magdy Fekry Hanna, Victoria Cookson, Oliver Mortusewicz, Thomas Helleday & Patrick Herr.
   NUDT22 promotes cancer growth through pyrimidine salvage.
   Oncogen, 42, 1282-1293 (2023). DOI: 10.1038/s41388-023-02643-4.
6. Irene Conforti, Andrea Benzi, Irene Caffa, Santina Bruzzone, Alessio Nencioni, Alberto Marra.
   Iminosugar-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Potential Anti-Pancreatic Cancer Agents.
   Pharmaceutics, 2023, 15, 1472. DOI: 10.3390/pharmaceutics15051472.
7. Biniecka P, Matsumoto S, Belotti A, Joussot J, Bai JF, Majjigapu SR, Thoueille P, Spaggiari D, Desfontaine V, Piacente F, Bruzzone S, Cea M, Decosterd LA, Vogel P, Nencioni A, Duchosal MA, Nahimana A.
   Anticancer Activities of Novel Nicotinamide Phosphoribosyltransferase Inhibitors in Hematological Malignancies.
   Molecules, 2023 Feb 16;28(4):1897. DOI: 10.3390/molecules28041897. PMID: 36838885; PMCID: PMC9967653.
8. Fratta S, Biniecka P, Moreno-Vargas AJ, Carmona AT, Nahimana A, Duchosal MA, Piacente F, Bruzzone S, Caffa I, Nencioni A, Robina I.
   Synthesis and structure-activity relationship of new nicotinamide phosphoribosyltransferase inhibitors with antitumor activity on solid and haematological cancer.
   Eur J Med Chem, 2023 Mar 15;250:115170. DOI: 10.1016/j.ejmech.2023.115170. Epub 2023 Jan 31. PMID: 36787658.
9. Abbotto E, Scarano N, Piacente F, Millo E, Cichero E, Bruzzone S.
   Virtual Screening in the Identification of Sirtuins' Activity Modulators.
   Molecules, 2022 Sep 1;27(17):5641. DOI: 10.3390/molecules27175641.
10. Mishra S, Cosentino C, Tamta AK, Khan D, Srinivasan S, Ravi V, Abbotto E, Arathi BP, Kumar S, Jain A, Ramaian AS, Kizkekra SM, Rajagopal R, Rao S, Krishna S, Asirvatham-Jeyaraj N, Haggerty ER, Silberman DM, Kurland IJ, Veeranna RP, Jayavelu T, Bruzzone S, Mostoslavsky R, Sundaresan NR.
    Sirtuin 6 inhibition protects against glucocorticoid-induced skeletal muscle atrophy by regulating IGF/PI3K/AKT signaling.
    Nat Commun, 2022 Sep 15;13(1):5415. DOI: 10.1038/s41467-022-32905-w.
11. Nappi A, Miro C, Pezone A, Tramontano A, Di Cicco E, Sagliocchi S, Cicatiello AG, Murolo M, Torabinejad S, Abbotto E, Caiazzo G, Raia M, Stornaiuolo M, Antonini D, Fabbrocini G, Salvatore D, Avvedimento VE, Dentice M.
    Loss of p53 activates thyroid hormone via type 2 deiodinase and enhances DNA damage.
    Nat Commun, 2023 Mar 4;14(1):1244. DOI: 10.1038/s41467-023-36755-y.
12. Wang C, Barnoud C, Cenerenti M, Sun M, Caffa I, Kizil B, Bill R, Liu Y, Pick R, Garnier L, Gkountidi OA, Ince LM, Holtkamp S, Fournier N, Michielin O, Speiser DE, Hugues S, Nencioni A, Pittet MJ, Jandus C, Scheiermann C.
    Dendritic cells direct circadian anti-tumour immune responses.
    Nature, 2023 Feb;614(7946):136-143. DOI: 10.1038/s41586-022-05605-0. Epub 2022 Dec 5. PMID: 36470303; PMCID: PMC9891997.
13. Agata Sofia Assuncao Carreira, Silvia Ravera, Chiara Zucal, Natthakan Thongon, Caffa Irene, Cecilia Astigiano, Nadia Bertola, Arianna Buongiorno, Michela Roccuzzo, Alessandra Bisio, Barbara Pardini, Alessio Nencioni, Santina Bruzzone, Alessandro Provenzani.
    Mitochondrial rewiring drives metabolic adaptation to NAD(H) shortage in triple negative breast cancer cells.
    Neoplasia, 2023, 41, DOI: 10.1016/j.neo.2023.100903.
14. Franco J, Piacente F, Walter M, Fratta S, Ghanem M, Benzi A, Caffa I, Kurkin AV, Altieri A, Herr P, Martínez-Bailén M, Robina I, Bruzzone S, Nencioni A, Del Rio A.
    Structure-Based Identification and Biological Characterization of New NAPRT Inhibitors.
    Pharmaceuticals, 2022, 15, 855. DOI: 10.3390/ph15070855.
15. Irene Conforti, Alberto Marra.
    Iminosugars as glycosyltransferase inhibitors.
    Org. Biomol. Chem., 2021, 19, 5439-5475. DOI: 10.1039/d1ob00382h.
16. Moustafa S. Ghanem, Fiammetta Monacelli and Alessio Nencioni.
    Advances in NAD-Lowering Agents for Cancer Treatment.
    Nutrients, 2021, 13(5), 1665. DOI: https://doi.org/10.3390/nu13051665.
17. Pamela Becherini, Irene Caffa, Francesco Piacente, Patrizia Damonte, Valerio Vellone, Mario Passalacqua, Andrea Benzi, Tommaso Bonfiglio, Daniele Reverberi, Amr Khalifa, Moustafa Ghanem, Ana Guijarro, Luca Tagliafico, Marzia Sucameli, Angelica Persia, Fiammetta Monacelli, Michele Cea, Santina Bruzzone, Silvia Ravera, and Alessio Nencioni.
    SIRT6 enhances oxidative phosphorylation in breast cancer and promotes mammary tumorigenesis in the mouse.
    Cancer & Metabolism, 9, Article number: 6 (2021). DOI: https://doi.org/10.1186/s40170-021-00240-1
18. Francesca Arruga, Sara Serra, Nicoletta Vitale, Giulia Guerra, Andrea Papait, Benjamin Baffour Gyau, Francesco Tito, Dimitar Efremov, Tiziana Vaisitti, Silvia Deaglio.
    Targeting of the A2A adenosine receptor counteracts immunosuppression in vivo in a mouse model of chronic lymphocytic leukemia.
    Haematologica, Early view Apr 16, 2020. DOI: 10.3324/haematol.2019.242016.
19. Francesca Arruga, Benjamin Baour Gyau, Andrea Iannello, Nicoletta Vitale, Tiziana Vaisitti and Silvia Deaglio.
    Immune Response Dysfunction in Chronic Lymphocytic Leukemia: Dissecting Molecular Mechanisms and Microenvironmental Conditions.
    International Journal of Molecular Sciences, 2020 Mar; 21(5): 1825.DOI: 10.3390/ijms21051825.

Publications produced by PIs

1. Valentina Audrito, Vincenzo Gianluca Messana, Silvia Deaglio (2020).
   NAMPT and NAPRT: Two Metabolic Enzymes With Key Roles in Inflammation.
   Front. Oncol., 19 March 2020. DOI: https://doi.org/10.3389/fonc.2020.00358.
2. Tiziana Vaisitti, Francesca Arruga, Giulia Guerra, Silvia Deaglio.
   Ectonucleotidases in Blood Malignancies: A Tale of Surface Markers and Therapeutic Targets.
   Front. Immunol., 04 October 2019. DOI: https://doi.org/10.3389/fimmu.2019.02301.
3. Valentina Audrito, Antonella Managò, Federica Gaudino, Leonardo Sorci,Vincenzo Gianluca Messana, Nadia Raffaelli and Silvia Deaglio.
   NAD-Biosynthetic and Consuming Enzymes as Central Players of Metabolic Regulation of Innate and Adaptive Immune Responses in Cancer.
   Front. Immunol., 25 July 2019. DOI: https://doi.org/10.3389/fimmu.2019.01720.